glp-1 liver mimetics as a potential therapy for nonalcoholic steatohepatitis GLP-1 mimetics as a potential

Although, in the last 10 years, the use of GLP-1 RAs, especially semaglutide and liraglutide, has increased, its clinical implications and how it affects metabolic parameters have yet to be fully consolidated

GLP-1 Patent Expiry: The Next Big Pharma Race Has Already Begun GLP-1 agonists like semaglutide, tirzepatide, and liraglutide have completely reshaped the global diabetes and obesity landscape

Insulin []

Patients with type 2 diabetes who are prescribed liraglutide have a 179% higher likelihood of developing non-arteritic anterior ischemic optic neuropathy (NAION), while those prescribed insulin have an 86% greater likelihood compared to patients who were prescribed other diabetes medications

However, PPGNTS neurons predominantly receive vagal input from oxytocin receptor-expressing vagal neurons, rather than those expressing GLP-1 receptors

Mounting research suggests GLP-1 drugs, which are used to treat diabetes and obesity, may one day help people with alcohol use disorder